Advisors Asset Management’s Summit Therapeutics SMMT Stock Holding History

Advisors Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$162K	Buy	11,123 +139	+1%	+$2.46K	﹤0.01%	1196
2026 Q1	$208K	Sell	10,984 -141	-1%	-$2.28K	﹤0.01%	1136
2025 Q4	$195K	Sell	11,125 -5	-0%	-$94	﹤0.01%	1137
2025 Q3	$230K	Sell	11,130 -43	-0.4%	-$1.04K	﹤0.01%	1097
2025 Q2	$238K	Buy	11,173 +6	+0.1%	+$137	﹤0.01%	1088
2025 Q1	$215K	Buy	11,167 +5,021	+82%	+$101K	﹤0.01%	1097
2024 Q4	$110K	Buy	+6,146	New	+$119K	﹤0.01%	1210

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Advisors Asset Management's SMMT Position: Q2 2026 in Review

Advisors Asset Management increased its Summit Therapeutics (SMMT) stake by 1.3% in Q2 2026, buying an estimated $2.46K and bringing the position to 11,123 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #1196.

Advisors Asset Management first reported a position in SMMT in Q4 2024 and has held it in 7 quarters since. The position peaked at $238K in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Advisors Asset Management held 11,123 shares of Summit Therapeutics worth $162K as of Q2 2026.
Advisors Asset Management bought 139 Summit Therapeutics shares in Q2 2026, an estimated $2.46K.
Summit Therapeutics made up ﹤0.01% of Advisors Asset Management's portfolio in Q2 2026, its #1196 holding.
Advisors Asset Management first reported a position in Summit Therapeutics in Q4 2024 and has held it in 7 quarters since.
Advisors Asset Management's Summit Therapeutics position peaked at $238K in Q2 2025.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.